AUROPHARMA

June 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR DYRUPEG FROM UK’S MHRA

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

May 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FIRST US FDA SUBMISSION PLANNED IN FY26

• AUROBINDO PHARMA - 8 BIOSIMILAR CANDIDATES WITH TAM OF GT50 BILLION USD IN 2030 UNDER DEVELOPMENT

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Adds analyst comment in paragraph 6-7, updates shares

May 12 (Reuters) - Indian pharma stocks .NIPHARM fell 1.6% on Monday, bucking broader market gains, after U.S. President Trump said he would cut drug prices by 30%–80% to match other wealthy nations.

Trump said he would sign an executive order on Monday to pursue "most favored nation" pricing.

The U.S. currently pays nearly three times more for many prescription drugs, though Trump offered no implementation details. Several Indian drugmakers earn a significant share of their revenue from North America by selling low-cost generic versions of newer drugs.

Thirteen of 20 stocks on the pharma sub-index fell, led by Sun Pharma’s 4.6% drop, even as the Nifty 50 .NSEI gained 2.5%; Zydus Life ZYDU.NS and Cipla CIPL.NS also declined 0.7% each.

Divi's Laboratories DIVI.NS and Lupin LUPN.NS fell 2% each, while Biocon BION.NS lost nearly 3%.

"A price cut of prescription drugs by 50% or more would hurt the U.S. formulations market, more on the branded size due to immediate potential impact, while over the medium term it will also impact generics as it reduces the potential market size of new drugs," said Shrikant Akolkar, an analyst at Nuvama Institutional Equities.

"Indian branded players like Sun Pharma, Biocon and Zydus Life may see an impact upon strict implementation," Akolkar said.

The U.S. accounts for nearly a third of India's pharma exports, which rose 16% to about $9 billion last fiscal year, according to government-backed trade body Pharmexcil.

(Reporting by Kashish Tandon in Bengaluru; Editing by Nivedita Bhattacharjee and Mrigank Dhaniwala)

(([email protected]; 8800437922;))

** Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees

** Unit receives U.S. FDA's approval for Dasatinib tablets

** Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26

** Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%

** Share price above 50-day, 100-day and 200-day exponential moving averages

** Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG

** Stock last up 4.1%, cutting YTD loss to 7.3%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Aurobindo Pharma ARBN.NS rises 3.8% to 1123 rupees, their biggest one-day gain in over a month

** ARBN biggest gainer in the Nifty pharma index .NIPHARM, which is up 1.8%

** Drug maker gets U.S. FDA's final approval to manufacture and market Rivaroxaban Tablets USP, 2.5 mg

** Drug, which is used to treat blood clots, will be launched in Q1FY26

** Avg of analysts' rating on the stock is "Buy;" median PT is 1463 rupees - data compiled by LSEG

** Stock down 16% YTD vs 11% decline in the pharma index

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.

U.S. accounts for a third of India's overall pharma exports.

Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.

On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.

Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.

Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.

The pharma index has fallen 14.4% this year.

(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)

(([email protected];))

By Kashish Tandon

April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.

"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.

"That will be announced in the near future, and is under review right now," Trump said.

The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.

All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.

Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.

Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.

Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.

However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.

"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.

Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.

Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

(([email protected]; 8800437922;))

April 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• FDA SAYS KETAMINE HYDROCHLORIDE INJECTION SHORTAGE RESOLVED AS OF APRIL 2 - WEBSITE

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

March 28 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• ACQUISITION IN SWARNAASKSHU SOLAR POWER EXPECTED TO BE COMPLETED BY JUNE 30

Source text: ID:nBSE5xtd9z

Further company coverage: ARBN.NS

(([email protected];;))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

March 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• US FDA CONDUCTED INSPECTION AT APITORIA PHARMA UNIT-V

• APITORIA PHARMA UNIT-V CLASSIFIED AS 'VOLUNTARY ACTION INDICATED' BY USFDA

Source text: ID:nNSE5xTcqG

Further company coverage: ARBN.NS

(([email protected];;))

March 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - TERMINATION OF LICENSE AGREEMENT WITH HILLEMAN LABORATORIES SINGAPORE PTE

• AUROBINDO PHARMA - TERMINATION OF AGREEMENT BY AURO VACCINES

• AUROBINDO PHARMA LTD - TERMINATION WILL NOT HAVE SIGNIFICANT IMPACT ON COMPANY FINANCIALS

Source text: ID:nnAPN2OO861

Further company coverage: ARBN.NS

(([email protected];))

By Jennifer Rigby and Lisa Baertlein

LONDON, Feb 21 (Reuters) - The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases including HIV and malaria in some of the world's poorest countries, and life-threatening gaps could persist for months, according to two sources familiar with the sector.

The U.S. Agency for International Development (USAID) usually places around $600 million of orders annually for products such as medicines, diagnostic tests and equipment like bed nets, as part of one of its biggest health supply contracts including HIV, malaria and reproductive health.

But the freeze has put orders and forecasts, particularly those made months in advance, on hold. That will likely have far-reaching implications for deliveries, cost, and timings, according to two sources with knowledge of the global health supply chain and others working in the sector.

Companies including the U.S. firm Abbott ABT.N, Switzerland's Roche ROG.S, and India's Cipla CIPL.NS are all likely to be affected, alongside others including Hologic HOLX.O, Viatris VTRS.O, Hetero and Aurobindo ARBN.NS, the first of the sources told Reuters.

"We are monitoring the situation closely. Our highest priority is to ensure that patients have continuous access to our diagnostic tests and treatments around the world," said a Roche spokesperson in response to Reuters' questions. The other companies either declined to comment or did not respond. The U.S. State Department did not immediately respond to requests for comment.

The first source said waivers from the U.S. government, intended to allow lifesaving work to restart, only applied to orders already moving around the world. Even those were not fully functional as the USAID payment system remained down, he said. Future funding and orders were more uncertain, even for companies where the raw materials have been assembled or the manufacturing capacity booked, he added.

Medicines and diagnostic tests for HIV and malaria, as well as preventive tools like bed nets and contraceptives, could be impacted, he said.

"There will be a huge backlog," said Fitsum Lakew Alemayehu, the African Union liaison manager at WACI Health, an African advocacy organization. "In Africa, millions have been on those treatments."

'BULLWHIP' EFFECT

The dismantling of USAID has already had significant impact across the globe, including shuttering HIV clinics, stranding emergency food aid, and halting research.

For medical supplies, the freeze could also hit prices, because companies have been able to operate more efficiently knowing that they would continue to get orders from USAID, all of the sources said.

Prashant Yadav, a medical supply chain expert and senior fellow at the nonpartisan Council on Foreign Relations think tank, said the upheaval could upend this system of advance demand forecasts entirely, hitting prices and ultimately risking budget shortfalls across other buyers, like governments and global health funders.

He said it was an example of the "bullwhip" effect in supply chains, where "any small changes, even if they are for a short duration of time, get amplified at every level in the system". The term is derived from a scientific concept in which movements of a whip are amplified from the origin - the hand cracking the whip - to the endpoint.

Even if the aid freeze ends after a 90-day review, as the Trump administration originally suggested, restarting production will be complex and there could be legal issues, several experts said.

"This is a huge mess to untangle," said Tom Cotter, chief executive officer at Health Response Alliance, a nonprofit organization dedicated to ensuring equitable access to health services during emergencies.

(Reporting by Jennifer Rigby, additional reporting by Maggie Fick in London, Rishika Sadam in Hyderabad)

(([email protected];))

** Shares of Aurobindo Pharma ARBN.NS fall 2.2% to 1,110.00 rupees, set for third straight session of losses

** US FDA classified inspection at co's unit's warehousing facility in New Jersey as 'Official Action Indicated'

** Official Action Indicated (OAI) classification indicates a facility is in an unacceptable state of compliance, per US FDA site

** The inspection, conducted from May 13-15 last year, was concluded with 5 observations

** ARBN fell 2.4% in previous session after US FDA issued five observations to subsidiary Eugia Steriles after a pre-approval inspection

** ARBN gained 23.1% in 2024

(Reporting by Vijay Malkar)

(([email protected];))

** Aurobindo Pharma ARBN.NS falls 2.8% to 1,130.30 rupees

** U.S. Food and Drug Administration issues five observations to co's step-down subsidiary Eugia Steriles after a pre-approval inspection

** ARBN says observations procedural in nature and will be responded to within stipulated time

** Around 2.9 mln shares traded, 3.2x the 30-day avg

** Stock among top losers on Nifty Pharma index .NIPHARM, which is down 0.5%

** NIPHARM fell after Donald Trump said he intended to impose tariffs of about 25% or higher on pharma imports

** ARBN gained 23.1% in 2024

(Reporting by Vijay Malkar)

(([email protected];))

Feb 18 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• COMPLETION OF US FDA PRE-APPROVAL INSPECTION AT EUGIA STERILES

• INSPECTION CONCLUDES WITH 5 PROCEDURAL OBSERVATIONS

Source text: ID:nBSE3PWnk0

Further company coverage: ARBN.NS

(([email protected];;))

Feb 7 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• US FDA INSPECTED AN API MANUFACTURING FACILITY, UNIT 2 OF APITORIA PHARMA

• US FDA ISSUED EIR CLASSIFYING FACILITY AS VAI

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

Feb 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA Q3 CONSOL NET PROFIT 8.46 BILLION RUPEES

• AUROBINDO PHARMA DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 79.79 BILLION RUPEES

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Jan 31 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FOR BIOSIMILAR DYRUPEG FROM EMA

• EXPECTED TO GET APPROVAL FOR DYRUPEG BY EUROPEAN COMMISSION IN APRIL 2025

Source text: ID:nBSE4gRFKt

Further company coverage: ARBN.NS

(([email protected];;))

Jan 28 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• UNIT 2 OF APITORIA PHARMA RECEIVED EIR FROM US FDA WITH VAI CLASSIFICATION

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

** Shares of drug maker Aurobindo Pharma ARBN.NS rise 4.6% to 1,246.9 rupees

** ARBN is the top gainer in pharma index .NIPHARM, which is up 1.4%

** Rise after CLSA upgrades stock to "outperform" from "hold"; TP at 1,400 rupees apiece, an 18% potential upside in the next 12 months

** ARBN poised to deliver fastest growth among Indian large-cap pharma peers, says CLSA

** Adds ARBN's U.S. business revenue will more than double in the next three years

** Says ARBN trades at a 15%-20% discount to its peers despite faster growth prospects, making it an attractive proposition

** ARBN has dropped 6.4% YTD, underperforming pharma index, which is down 4.5% - LSEG data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Aurobindo Pharma Ltd ARBN.NS rise as much as 2.5% to 1,244 rupees

** Pharma co says U.S. Food and Drug Administration (FDA) inspected an API manufacturing facility of a unit in Telangana state from Dec. 9-17

** Adds that inspection closed with two observations, which are procedural in nature and will be responded to within the stipulated time

** More than 415,000 shares traded as of 10:11 a.m. IST, vs their 30-day moving avg of over 1.1 mln shares

** Mean rating of 26 analysts rating the stock is "buy"; their median PT is 1,537.5 rupees - LSEG data

** ARBN last up 2%, adding to YTD gains of 14.4%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Dec 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - COMPLETION OF US FDA INSPECTION AT UNIT V OF APITORIA PHARMA

• AUROBINDO PHARMA - INSPECTION CLOSED WITH 2 OBSERVATIONS

Source text: ID:nBSE4PT6h0

Further company coverage: ARBN.NS

(([email protected];))

** Aurobindo Pharma ARBN.NS rises 1.7% to 1,228.55 rupees

** Pharma co's unit CuraTeQ Biologics says advisory committee to Europe's drug regulator recommends granting of marketing authorisation for its Zefylti drug

** Zefylti is a biosimilar of filgrastim drug, intended to treat neutropenia and mobilisation of peripheral progenitor cells

** Stock set to snap five-session losing streak

** ARBN up ~13% YTD; had gained 147% in 2023

(Reporting by Vijay Malkar)

(([email protected];))

Dec 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ BIOLOGICS RECEIVES POSITIVE OPINION FOR BIOSIMILAR ZEFYLTI

• EUROPEAN AGENCY ADOPTS POSITIVE OPINION FOR CURATEQ'S BIOSIMILAR ZEFYLTI

Source text: ID:nBSE6Z4CYp

Further company coverage: ARBN.NS

(([email protected];))

Dec 11 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• THERANYM BIOLOGICS ALLOTS 2,041 EQUITY SHARES TO DR. SATAKARNI MAKKAPATI

Source text: ID:nBSE9Vxj2Y

Further company coverage: ARBN.NS

(([email protected];;))

Dec 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - EUGIA PHARMA RECEIVES USFDA APPROVAL FOR PAZOPANIB TABLETS, 200 MG

Source text: ID:nnAZN2R7730

Further company coverage: ARBN.NS

(([email protected];;))

Dec 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CLARIFICATION ON NEWS APPEARED IN MEDIA ON KAKINADA SEAPORT & KAKINADA SEZ

• AUROBINDO PHARMA - CLARIFIES CO NOT CONNECTED WITH OWNERSHIP, OPERATIONS OF KAKINADA SEAPORTS, KAKINADA SEZ

Source text: ID:nBSE8r3K6r

Further company coverage: ARBN.NS

(([email protected];))

** Shares of Aurobindo Pharma ARBN.NS rise 2% to 1,495 rupees

** Analysts at BoB Capital Equity Research upgrade stock to "buy" from "hold"; hike PT to 1,728 rupees from 1,200 rupees

** Brokerage expects sales of $700 mln for co's injectables unit by FY26

** Adds, co's biosimilars will be launched by FY26, after which EBITDA margin is expected to increase to 24% by FY27 from 20% in FY24

** Says co has several growth including strong generics pipeline, commercialising its Pen-G project used to treat bacterial infections and growing injectables business

** Twenty-six analysts covering stock, on avg, have a "buy" rating; median PT 1,579.5 rupees - LSEG data

** Stock up 38% YTD vs 40% rise in Nifty pharma index .NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))